Tiziana Life Sciences, Ltd. (TLSA) - Dana dhuwit diétung saben saham

Tiziana Life Sciences (TLSA) combines strict bioethical ESG standards with the development of non-invasive mucosal antibody delivery methods. The free cash flow per share trend on the GURU.Markets consolidated chart resolves this contrast, where 0.02 marks a new level. However, its startup status creates financial pressure, as early-stage testing costs rapidly deplete existing reserves.
Rincian analitis perusahaan Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences focuses on R&D in the field of nasal immunotherapy, seeking to monetize patents through licensing agreements with big pharma. This indicator measures the liquid capital reserve per share, adjusted for one-time receipts, allowing investors to assess the company's financial autonomy during clinical trials by analyzing the dynamics of the free cash position per share.